The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > BUSINESS
BUSINESS
- M3 to Start “Web Lecture” Service for Drug Makers
September 19, 2011
- All-case PMS Completed for Colorectal Cancer Treatment Erbitux: Merck Serono
September 19, 2011
- Nippon Shinyaku Discloses Details on Halcion-Laced Liquor Incident
September 19, 2011
- Novartis Applies for Tobramycin for Cystic Fibrosis of Pancreas
September 19, 2011
- BMKK Files for Add’l Indications for 2 Drugs Based on Data in Public Domain
September 19, 2011
- Janssen Adds Precautions for Concerta for Patients Over 18
September 19, 2011
- Takeda to Initiate Domestic PIII Trial for Once-weekly DPP-4 Inhibitor
September 19, 2011
- Perampanel Improves Partial Epilepsy Seizures in Overseas PIII Trial
September 19, 2011
- Zonegran Shows High Efficacy for Pediatric Partial Epilepsy: Eisai
September 19, 2011
- NanoCarrier Obtains Substance Patent for Its “pH-Responsive Micelle” in China
September 19, 2011
- Sales of Ethical Drugs Up 0.1% in July: Crecon & Research Consulting
September 19, 2011
- Sandoz to Use Its Unique Anticancer Drug Container for More Anticancer Drugs
September 19, 2011
- Nichi-Iko, Pfizer Apply for Add’l Indication for Generic Cisplatin Using Data from Public Domain
September 19, 2011
- Astellas, UMN Pharma Complete Cell Culture–based Flu Vaccine Inoculation of Subjects in PI/PII Trials
September 16, 2011
- OncoTherapy Completes Patient Enrolment for PII Trial of Angiogenesis Inhibitor
September 16, 2011
- Everolimus Obtains EU Approval for SEGA: Novartis
September 16, 2011
- Ono Pharmaceutical Licenses Ca Receptor Agonist from US Company
September 16, 2011
- Ono Licenses in Ion Channel Inhibitor Ivabradine from Servier
September 15, 2011
- Small, Medium-Sized Generic Drug Makers’ Business Improves Amid Uncertainty Over Future
September 15, 2011
- Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept
September 15, 2011
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…